Effects of extracellular magnesium extract on the proliferation and differentiation of human osteoblasts and osteoclasts in coculture
Source abstract
Abstract
Coculture of osteoblasts and osteoclasts is a subject of interest in the understanding of how magnesium (Mg)-based implants influence the bone metabolism and remodeling upon degradation. Human telomerase reverse transcriptase (hTERT) transduced mesenchymal stem cells (SCP-1) were first differentiated into osteoblasts with osteogenic supplements and then further cocultured with peripheral blood mononucleated cells (PBMC) without the addition of osteoclastogenesis promoting factors. Concomitantly, the cultures were exposed to variable Mg extract dilutions (0, 30×, 10×, 5×, 3×, 2× and 1×). Phenotype characterization documented that while 2× dilution of Mg extract was extremely toxic to osteoclast monoculture, monocytes in coculture with osteoblasts exhibited a greater tolerance to higher Mg extract concentration. The dense growth of osteoblasts in cultures with 1× dilution of Mg extract suggested that high concentration of Mg extract promoted osteoblast proliferation/differentiation behavior. The results of intracellular alkaline phosphatase (ALP) and tartrate-resistant acid phosphatase (TRAP) activities as well as protein and gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and osteoclast-associated receptor (OSCAR) revealed significantly enhanced formation of osteoblasts whereas decreased osteoclastogenesis in the cultures with high concentrations of Mg extract (2× and 1× dilutions). In conclusion, while an increased osteoinductivity has been demonstrated, the impact of potentially decreased osteoclastogenesis around the Mg-based implants should be also taken into account. Cocultures containing both bone-forming osteoblasts and bone-resorbing osteoclasts should be preferentially performed for in vitro cytocompatibility assessment of Mg-based implants as they more closely mimic the in vivo environment. Statement of significance An attractive human osteoblasts and osteoclasts cocultivation regime was developed as an in vitro cytocompatibility model for magnesium implants. Parameters in terms of cellular proliferation and differentiation behaviors were investigated and we conclude that high concentration of magnesium extract could lead to a promotion in osteoblastogenesis but an inhibition in osteoclastogenesis. It could contribute to the repeated observations of enhanced bone growth adjacent to degradable magnesium alloys. More interestingly, it demonstrates that compared to monoculture, osteoclasts in cocultures with osteoblasts exhibited higher tolerance to the culture environment with high magnesium extract. It might attribute to the neutralization process of the alkaline medium by acid generated by increased amount of osteoblasts in the condition with high concentration of Mg extract. The submitted work could be of significant importance to other researchers working in the related field(s), thus appealing to the readership of Acta Biomaterialia.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Magnesium Alloys: Properties and Applications · Bone Tissue Engineering Materials · Magnesium in Health and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Magnesium and its alloys as orthopedic biomaterials: a review10.1016/j.biomaterials.2005.10.003 ↗
2. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?10.1136/heart.89.6.651 ↗
3. Magnesium chemistry and biochemistry10.1023/A:1016058229972 ↗
4. In vivo corrosion behavior of Mg–Mn–Zn alloy for bone implant application10.1002/jbm.a.31273 ↗
5. In vivo corrosion of four magnesium alloys and the associated bone response10.1016/j.biomaterials.2004.09.049 ↗
6. In vitro and in vivo corrosion measurements of magnesium alloys10.1016/j.biomaterials.2005.07.037 ↗
7. Biodegradable magnesium scaffolds: part 1: appropriate inflammatory response10.1002/jbm.a.31170 ↗
8. Biodegradable magnesium scaffolds: part II: peri-implant bone remodeling10.1002/jbm.a.31293 ↗
9. Research on an Mg–Zn alloy as a degradable biomaterial10.1016/j.actbio.2009.06.028 ↗
10. The development of binary Mg–Ca alloys for use as biodegradable materials within bone10.1016/j.biomaterials.2007.12.021 ↗
11. Synthesis of functionally graded MgCO3 apatite accelerating osteoblast adhesion10.1002/jbm.10220 ↗
12. Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants10.1002/jbm.10270 ↗
13. Human osteoblasts adhesion and proliferation on magnesium-substituted tricalcium phosphate dense tablets10.1007/s10856-008-3610-3 ↗
14. Osteoblastic cell response on fluoridated hydroxyapatite coatings: the effect of magnesium incorporation10.1088/1748-6041/5/5/054114 ↗
15. Osteoblast response to magnesium ion-incorporated nanoporous titanium oxide surfaces10.1111/j.1600-0501.2010.01944.x ↗
16. Importance of melastatin-like transient receptor potential 7 and cations (magnesium, calcium) in human osteoblast-like cell proliferation10.1111/j.1365-2184.2007.00476.x ↗
17. Cellular and molecular mechanisms of bone remodeling10.1074/jbc.R109.041087 ↗
18. Molecular biology of bone remodelling
19. Effects of extracellular magnesium on the differentiation and function of human osteoclasts10.1016/j.actbio.2014.02.010 ↗
20. Osteoblasts and their applications in bone tissue engineering
21. T. Phan, J. Xu, M. Zheng, Interaction between osteoblast and osteoclast: impact in bone disease, 2004.
22. Cell biology of the osteoclast10.1016/S0301-472X(99)00061-2 ↗
23. Osteoclasts and biomaterials10.1007/s00068-006-6043-1 ↗
24. 10993-5:2009 I. Biological evaluation of medical devices. Part 5. Tests for in vitro cytotoxicity, 2009.
25. 10993-12:2012 I. Biological evaluation of medical devices. Part 12. Sample preparation and reference materials, 2012.
26. Variables in the isolation and culture of human monocytes that are of particular relevance to studies of HIV10.1002/jlb.56.3.236 ↗
27. Resorbability of bone substitute biomaterials by human osteoclasts10.1016/j.biomaterials.2003.10.079 ↗
28. Development of an osteoblast/osteoclast co-culture derived by human bone marrow stromal cells and human monocytes for biomaterials testing10.22203/eCM.v021a07 ↗
29. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I ↗
30. G. Jones, M. Marshall, A. El Haj, A. Motta, S. Cartmell. The use of osteoblast/osteoclast co-cultures on PLLA, silk and dentine scaffolds. Tissue Engineering: Mary Ann Liebert Inc 140 Huguenot Street, 3rd fl, New Rochelle, NY 10801, USA, 2007, pp. 1765–1766.
31. Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker10.1016/0168-1656(92)90158-6 ↗
32. Prion protein aggregation and neurotoxicity in cortical neurons10.1196/annals.1397.088 ↗
33. QBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data10.1186/gb-2007-8-2-r19 ↗
34. Effect of surface pre-treatments on biocompatibility of magnesium10.1016/j.actbio.2009.04.018 ↗
35. Optimization of cell adhesion on Mg based implant materials by pre-incubation under cell culture conditions10.3390/ijms15057639 ↗
36. Protective effect of calcium deficiency on the inflammatory response in magnesium-deficient rats10.1007/s00394-002-0376-0 ↗
37. Effect of magnesium supplementation on oxidative stress in alloxanic diabetic rats
38. A. Rosanoff, The 2-to-1 Calcium-to-Magnesium Ratio.
39. Osteoclast differentiation and activation10.1038/nature01658 ↗
40. The molecular understanding of osteoclast differentiation10.1016/j.bone.2006.09.023 ↗
41. New insights into osteoclastogenic signaling mechanisms10.1016/j.tem.2012.05.005 ↗
42. Bone remodelling at a glance10.1242/jcs.063032 ↗
43. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density10.1016/S0092-8674(00)80209-3 ↗
44. Osteoprotegerin: a new therapeutic agent for the treatment of bone disease10.1016/S1359-6446(01)02037-2 ↗
45. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle10.1359/jbmr.040113 ↗
46. The ratio of messenger RNA levels of receptor activator of nuclear factor κB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis10.1359/jbmr.2001.16.6.1015 ↗
47. Acid-base imbalance and the skeleton10.1007/s394-001-8351-5 ↗
48. Receptor functions for the integrin VLA-3: fibronectin, collagen, and laminin binding are differentially influenced by Arg–Gly–Asp peptide and by divalent cations10.1083/jcb.112.1.169 ↗
49. Roles of magnesium and calcium ions in cell-to-substrate adhesion10.1016/0014-4827(72)90480-6 ↗
50. Magnesium hydroxide temporarily enhancing osteoblast activity and decreasing the osteoclast number in peri-implant bone remodelling10.1016/j.actbio.2009.12.037 ↗